NewsBenzingaReportado el domingo, IDEAYA nomina IDE101, un potencial inhibidor dual de CDK primero en su clase dirigido a la deficiencia de CDKN2A en tumores sólidos, con presentación de IND prevista para el primer semestre de 2027 Reportado el domingo, IDEAYA nomina IDE101, un potencial inhibidor dual de CDK primero en su clase dirigido a la deficiencia de CDKN2A en tumores sólidos, con presentación de IND prevista para el primer semestre de 2027 Benzinga 2026.11.16 05:19 (GMT+0) Open on Benzinga Other news Reported Sunday, Alpha Tau’s Alpha DaRT Achieves 100% Feasibility In 8 Recurrent Glioblastoma Patients, With Five Complete Responses And One Partial Response Among Six Evaluable Patients And No Unanticipated Serious Adverse Events Reported Sunday, IDEAYA Nominates IDE101, Potential First-In-Class Dual CDK Inhibitor Targeting CDKN2A-Deficiency In Solid Tumors, With IND Filing Planned For H1 2027 Nasdaq Falls Over 200 Points but Still Posts Weekly Gain; Investor Sentiment Weakens as Fear & Greed Index Remains in 'Fear' Zone Tyson Foods, Aramark and 3 Stocks to Watch Heading Into Monday HSBC Downgrades Nvidia to Hold, Cuts Price Target From $365 to $170 Flight Meltdown Enters Day 3: JetBlue, American Still Scrambling After FAA Router Failure
Reported Sunday, Alpha Tau’s Alpha DaRT Achieves 100% Feasibility In 8 Recurrent Glioblastoma Patients, With Five Complete Responses And One Partial Response Among Six Evaluable Patients And No Unanticipated Serious Adverse Events
Reported Sunday, IDEAYA Nominates IDE101, Potential First-In-Class Dual CDK Inhibitor Targeting CDKN2A-Deficiency In Solid Tumors, With IND Filing Planned For H1 2027
Nasdaq Falls Over 200 Points but Still Posts Weekly Gain; Investor Sentiment Weakens as Fear & Greed Index Remains in 'Fear' Zone